Health news
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for risdiplam for use in presymptomatic infants less than 2 months of age with spinal muscular atrophy (SMA).…
The Food and Drug Administration (FDA) has approved Skyrizi® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA). Skyrizi is also indicated for the treatment of moderate to severe plaque psoriasis in adults…
A supplemental Biologics License Application (sBLA) has been submitted to the Food and Drug Administration (FDA) for pegloticase injection plus methotrexate for the treatment of uncontrolled gout. Pegloticase is currently marketed under the brand name…
The Food and Drug Administration (FDA) has granted Fast Track designation to DYN101 for the treatment of myotubular and centronuclear myopathies (CNM). Centronuclear and myotubular myopathies (CNM) are rare, life-threatening disorders characterized by muscle weakness…
The Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older and active juvenile psoriatic arthritis (JPsA) in patients 2…
The Food and Drug Administration (FDA) has approved Yusimry (adalimumab-aqvh), a biosimilar to Humira® (adalimumab). Yusimry, a tumor necrosis factor (TNF) blocker, is indicated for: Rheumatoid arthritis (RA): reducing signs/symptoms, inducing major clinical response, inhibiting…
Interim results were announced from a phase 3 study evaluating bimekizumab, an investigational interleukin (IL)-17A and IL-17F inhibitor, in adults with active ankylosing spondylitis. The ongoing multicenter, randomized, double-blind, placebo-controlled BE MOBILE 2 study (ClinicalTrials.gov…
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Xeljanz®/Xeljanz® XR (tofacitinib) for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance…
AbbVie has updated the prescribing information and medication guide for Rinvoq® (upadacitinib) to include additional information related to risks associated with systemically-administered Janus kinase (JAK) inhibitors used in the treatment of rheumatoid arthritis (RA) and…
Treatment with guselkumab, an interleukin-23 antagonist, was associated with significant improvements in joint and skin manifestations in patients with active psoriatic arthritis (PsA) with inadequate response to tumor necrosis factor inhibitors (TNFi), according to data…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021